Thank you Trading ..ok early treatment most important , maybe this is why FDA was asking questions about pediatrics .

That reminded me about some other study , the Italian study with 40 patients in vitro , those patients were MDR -4. and they were resistant to Maraviroc ,
Well , apparently that too was not a problem for Leronlimab since they be presenting during CROI ..,,
We heard in the past that Leronlimab may work when patient resistant to Maraviroc ..

Wow , I honestly myself have a problems to see how this little molecules is working ...but I am so
proud I am a part of it ...,

Thank you ..


All in my opinion .